title: Management of traumatic haemorrhage--the European perspective.
abstract: Trauma-induced coagulopathy represents a life-threatening complication in severely injured patients. To avoid exsanguination, rapid surgical bleeding control coupled with immediate and aggressive haemostatic treatment is mandatory. In most trauma centres, coagulation therapy is established with transfusion of high volumes of fresh frozen plasma. Due to logistic issues, only busy trauma facilities store pre-thawed plasma ready for immediate transfusion. Thus, substantial time delays have been reported between the first unit of red blood cells transfused and the administration of fresh frozen plasma. An alternative for rapid improvement of haemostatic capacity is purified coagulation factor concentrates. They contain a well-defined concentration of coagulation proteins, carry a low risk for transfusion-related lung injury and virus transmission, and are available for immediate use without the need for blood group matching. In some European trauma centres, treatment algorithms have been developed for the administration of coagulation factor concentrates based on visco-elastic test results.
authors.affiliation: Department of Anaesthesiology and Intensive Care, AUVA Trauma Centre, Salzburg, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Schöchl
authors.forename: W
authors.initials: W
authors.lastname: Voelckel
authors.forename: C J
authors.initials: CJ
authors.lastname: Schlimp
mesh_terms: D001778:Blood Coagulation Disorders / Q000175:diagnosis; D005060:Europe; D006470:Hemorrhage / Q000628:therapy*; D006801:Humans; D017713:Platelet Transfusion; D013917:Thrombin / Q000096:biosynthesis; D014148:Tranexamic Acid / Q000627:therapeutic use; D014947:Wounds and Injuries / Q000150:complications*
chemical_list: D014148:Tranexamic Acid; D013917:Thrombin